DIRS.INFO The most relevant business & tech news

☆ Popular weight-loss and diabetes medications show promise for curbing smoking, study suggests
▼ + stars: | 2024-07-29 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +4 min

But experts emphasize that much more research is needed before using the medications off-label for smoking cessation. In a study published Monday in the journal Annals of Internal Medicine, researchers tracked the medical records of more than 200,000 people who started medications to treat type 2 diabetes, including nearly 6,000 people using semaglutide medications such as Ozempic. Over the course of a year, people who started using semaglutide were significantly less likely to have medical encounters for tobacco use disorders, prescriptions for medications for smoking cessation or counseling for smoking cessation than those who started other diabetes medications such as insulin and metformin. “A signal like this one cannot be ignored, particularly because of how consequential it could be if, in fact, we can have now a new medication for treating smoking cessation,” she said. But fewer than 1 in 10 adult cigarette smokers succeed in quitting each year, according to the new study, and options for smoking cessation treatment haven’t changed much in decades.

Persons: Disha, ”, Nora Volkow, ” Volkow, Dr, Sanjay Gupta, Volkow Organizations: CNN, Internal Medicine, Endeavor Health, National Institute on Drug, Get CNN, CNN Health, US Centers for Disease Control, American Cancer Society Locations: Chicago, United States

☆ Popular weight loss and diabetes drugs linked to increased risk of rare form of blindness
▼ + stars: | 2024-07-03 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +6 min

CNN —People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide. Semaglutide prescriptions have soared in the US, which could raise the number of people at risk for a potential side effect. But the large number of people who are taking semaglutide should raise confidence that the absolute risk of developing NAION as a result is rare.

Persons: ”, Joseph Rizzo, ” Susan Mollan, Disha, Dr, Sanjay Gupta, Chanapa, Andrew Lee, ” Narang Organizations: CNN —, Mass, Novo Nordisk, CNN, Harvard Medical School, ”, University Hospitals Birmingham, Endeavor Health, CNN Health, US Food and Drug Administration, FDA, American Academy of Ophthalmology, Houston Methodist Hospital Locations: Chicago

☆ Many people using GLP-1s for weight loss stop treatment too soon, research shows, and results are not one-size-fits-all
▼ + stars: | 2024-05-21 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +8 min

Professional organizations have set this as a guideline for when to reassess whether a treatment is providing clinically meaningful weight loss. People who met with their providers less frequently – and those living in underserved regions with broader health inequities – were more likely to discontinue GLP-1 treatment sooner. But using GLP-1 treatments are still an investment in many ways. These injected medications, called GLP-1 agonists, are in high demand because they have proved to be so effective for weight loss. And experts warn that the GLP-1 treatment process can be different for everyone.

Persons: ”, Disha, Wegovy, Jody Dushay, Beth, There’s, Razia Hashmi, ” Hashmi, it’s, “, Dr, Sanjay Gupta, ” Narang, ” Dushay Organizations: CNN, Endeavor Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Shield, Dandelion Health, CNN Health, “ Locations: Chicago, –, GLP

☆ Oprah Winfrey tears up recounting her weight loss journey in primetime special
▼ + stars: | 2024-03-18 | by ( Megan Thomas | ) edition.cnn.com time to read: +3 min

CNN —It’s been nearly 13 years since “The Oprah Winfrey Show” came to an end, but for viewers of her weight loss special on Monday night, it likely felt like Winfrey’s talk show was back. “An Oprah Special: Shame, Blame and the Weight Loss Revolution” featured Winfrey doing what she proved for 25 seasons on “The Oprah Winfrey Show” she can do better than just about anyone else: bring people together and get them talking – and listening – to each other. Winfrey, too, shared the pain she has felt at times in her weight journey. “It’s not a matter of willpower.”The medical experts addressed potential side effects of weight loss medications and factors and risks that should be considered before taking it as part of a multiifaceted care plan. Winfrey spoke about her use of weight loss medication as one “tool” to manage her weight, combined with hiking, running, weight resistance training and eating a healthy diet.

Persons: CNN — It’s, Oprah Winfrey, ”, “, Winfrey, ” Winfrey, Scott Butsch, Amanda Velazquez, It’s, ” Butsch, “ It’s, Let’s Organizations: CNN, Obesity, Metabolic, Cleveland Clinic Locations: United States, Sinai, Los Angeles

☆ Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +23 min

Novo spent at least $25.8 million over the past decade on U.S. medical professionals to promote its two obesity drugs, Wegovy and Saxenda, the analysis found. Jastreboff has also worked on clinical trials of obesity drugs for Eli Lilly, which markets a Wegovy competitor. Some doctors said Novo’s payments exemplify how the flood of industry money can dominate decision-making about care and coverage. Government pharmacy officer Solaru said her agency concluded that the new obesity drugs could be cost-effective by preventing other weight-related diseases and boosting workplace productivity. In January, the personnel office told its health plans they must cover at least one GLP-1 obesity drug for 8 million workers, retirees and family members.

Persons: Lee Kaplan, Kaplan, ”, gastroenterologist, He’s, Novo, Donna Ryan, Ryan, “, ” Kaplan, ” Novo, Robert Lustig, “ I’m, Lustig, They’re, Ania, ” Jastreboff, Jastreboff, Eli Lilly, Lilly’s Zepbound, Lilly, ” Lilly, Novo’s, Ayana, Sanders, Arthur Kellermann, ” Kellermann, mouthpieces, ’ ”, “ I'm, Jamy Ard, Ard, Dele, ” Solaru, ” Ryan, Scott Kahan, Kahan, Solaru, Christine Gallagher, Wegovy, Rebekah Carl, Carl, Jen Wexler, gaunt, Wexler Organizations: Novo Nordisk, Dartmouth, Nutrition Institute, Massachusetts General Hospital, Harvard Medical School, Reuters, Cambridge, Obesity Society, U.S ., Management, Reuters . Pharmaceutical, ”, U.S, United, National Health Service, University of California, U.S . Food, Drug Administration, Doctors, Wegovy’s, BMI, Yale University’s Center, Weight Management, Wall Street, American Medical Association, Rutgers University’s School of Public Health, Affordable, . Pharmaceutical, Companies, Uniformed Services University of Health Sciences, Wake Forest University, Wake Forest Baptist Health Weight Management, Obesity, Pennington Biomedical Research, U.S . National Institutes of Health, Personnel Management, Coalition, STOP, George Washington University, Novo Locations: CAMBRIDGE, Massachusetts, Boston, U.S, Novo, Danish, United States, Louisiana, San Francisco, Wegovy, Pennington, Baton Rouge , Louisiana, Government, New Columbia , Pennsylvania, Florida

☆ Here's why we need insurance coverage for obesity treatment
▼ + stars: | 2023-11-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHere's why we need insurance coverage for obesity treatmentDr. Angela Fitch, Knownwell chief medical officer and president of Obesity Medicine Association, joins 'Squawk Box' to discuss the latest study from weight-loss drug Wegovy, what the advancement in weight-loss drugs means for the obesity epidemic in the U.S., and more.

Persons: Angela Fitch Organizations: Obesity Medicine Association Locations: U.S

☆ Doctors are racing to get certified to treat obesity as Americans clamor for weight-loss drugs
▼ + stars: | 2023-09-20 | by ( ) www.businessinsider.com time to read: +4 min

Almost 1,900 doctors signed up to take this year's exam to get certified in obesity medicine. Almost 1,900 doctors signed up to take the annual exam in October to become certified in obesity medicine, according to data the American Board of Obesity Medicine shared with Insider. The drugs, along with other new obesity treatments, have also piqued doctors' interest, said Dr. Kimberly Gudzune, the medical director of the American Board of Obesity Medicine, which administers the test. The American Board of Obesity Medicine, established in 2011, administered the first test to become certified in 2012. Since then, the number of doctors certified in obesity medicine has grown from fewer than 600 in 2013 to more than 6,700, according to the board.

Persons: Kimberly Gudzune, Gudzune Organizations: Morning, American Board of Obesity, American Medical Association, American, of Obesity Medicine, Centers for Disease Control

☆ Here are Friday's biggest analyst calls: Nvidia, Amazon, Carvana, Roku, Microsoft, Eli Lilly and more
▼ + stars: | 2023-07-21 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Truist reiterates Amazon as buy Truist said it's bullish heading into Amazon earnings Aug. 3. Piper Sandler upgrades SL Green to overweight from neutral Piper Sandler said in its upgrade of SL Green that the real estate investment trust has "favorable tailwinds." Piper Sandler downgrades Discover to neutral from overweight Piper Sandler said in its downgrade of the credit card company that it sees too many negative catalysts. Piper Sandler downgrades Carvana to neutral from overweight Piper Sandler downgraded the online used-car company mainly on valuation. Sirius' stock price has more than doubled over the past month and increased 42% yesterday alone.

Persons: . Bank of America downgrades Herc, Herc, Underperform, KeyBanc, it's, Truist, Piper Sandler, Piper Sandler downgrades Carvana, JPMorgan downgrades Blackstone, Morgan Stanley, Eli Lilly, Davidson, Davison, Oppenheimer, Baird, Wedbush, Goldman Sachs Organizations: . Bank of America, . Bank of America downgrades Herc Holdings, Bank of America, Hollywood, NA, Green, DFS, JPMorgan, Novo Nordisk, BMO, Consolidated Edison, of America, Deutsche Bank, Sirius, Nvidia, Microsoft Locations: 2Q23

☆ New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studies
▼ + stars: | 2023-06-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNew developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studiesDr. Angela Fitch, Knownwell chief medical officer and president of Obesity Medicine Association, joins 'Squawk Box' to discuss the advances in weight-loss drugs, what it means for the obesity epidemic in the U.S., and more.

Persons: Eli Lilly, Angela Fitch Organizations: Novo Nordisk, Pfizer, Obesity Medicine Association Locations: U.S

☆ Novo Nordisk rivals see room to compete in $100 billion weight-loss drug market
▼ + stars: | 2023-05-04 | by ( Michael Erman | ) www.reuters.com time to read: +6 min

The company has two oral GLP-1 drugs in mid-stage trials, and aims to choose one for a late-stage trial this year. He forecasts GLP-1s or similar drugs topping $100 billion in annual sales early in the 2030s, with Lilly's product accounting for more than $50 billion in sales. Smaller biotechs are also vying for a piece of the obesity market and hope large pharmaceutical companies will pay up for partnerships. "I don't know if it's $90 billion or $80 billion or $50 billion. The current GLP-1 drugs can cause nausea and vomiting.

☆ People Can't Get Ozempic, New Weight-Loss Drugs Because of Broken Healthcare System
▼ + stars: | 2023-04-13 | by ( ) www.businessinsider.com time to read: +15 min

Wegovy is just one of a wave of revolutionary weight-loss drugs, which also includes the buzzy Ozempic, that represents a watershed moment for obesity treatment. Demand for weight-loss drugs is surgingDoctors and healthcare professionals searched for a healthy, safe, and effective weight-loss solution for years before the drugs, known collectively as GLP-1 agonists, exploded on the scene. If there is one key that could unlock access to expensive weight-loss drugs for Americans, it's Medicare. Expanding coverage for Ozempic and other weight-loss drugs for just a small segment of the population could cost Medicare up to $26.8 billion a year. Patients lose outYears from now, patients may have an easier time getting their hands on weight-loss drugs.

☆ Workers are clamoring for pricey new weight-loss drugs like Ozempic. Companies are grappling with how to respond.
▼ + stars: | 2023-03-06 | by ( ) www.businessinsider.com time to read: +10 min

Companies that pay for workers' health insurance are grappling with how to cover the pricey drugs. Medicare, the federal program that provides health coverage for people 65 and older, doesn't cover weight-loss drugs. ArcBest already has a program to help workers lose weight through behavior changes and nutrition. Krutsch said he wants to build on that, covering the weight-loss drugs Wegovy and Saxenda for employees who aren't able to lose weight without medication. The new weight-loss drugs were in short supply in 2022, and that gave employers time to figure out how to handle them, he said.

☆ Weight loss startups offer access to new drugs, but do they provide good care?
▼ + stars: | 2022-11-13 | by ( Darius Tahir | Kaiser Health News | ) www.nbcnews.com time to read: +11 min

Now a wave of startups offer access to a new category of drugs coupled with intensive behavioral coaching online. These patients pay hundreds, if not thousands, of dollars, to access new drugs, called GLP-1 agonists, along with online coaching to encourage healthy habits. (That price includes generic drugs, but not the newer GLP-1 agonists, like Wegovy.) The firms say they’re on the vanguard of weight care, both citing the influence of biology and other scientific factors as key ingredients to their approaches. Found said older generics like zonisamide are more accessible than the GLP-1 agonists advertised on social media and their own website.

Search resuls for: "of Obesity Medicine"

13 mentions found